WORLD PRECLINICAL CONGRESS June 14-17, 2016 Westin Boston Waterfront, Boston, MA

First Page		Document Content
Date: 2016-04-07 10:46:41 Medicine Clinical medicine Medical research Virotherapy Drug discovery Pharmaceutical industry Experimental cancer treatments Immunotherapy Drug development Pre-clinical development Oncolytic virus		WORLD PRECLINICAL CONGRESS June 14-17, 2016 Westin Boston Waterfront, Boston, MA Add to Reading List Source URL: www.worldpreclinicalcongress.com Download Document from Source Website File Size: 258,20 KB Share Document on Facebook

	Final Results of a Phase II Multicenter Trial of HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab Combination Treatment in Patients with Stage IIIB-IV Unresectable or Metastatic Melanoma Abstract #1664 DocID: 1v2ur - View Document
	Tumor response from Phase II study of combination treatment of intratumoral HF10, a replication - competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melano DocID: 1uTz9 - View Document
	When Patients Win, We All Win™ Provectus Biopharmaceuticals, Inc Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigation DocID: 1rgN5 - View Document
	Intralesional therapy is a possible treatment option for patients with metastatic melanoma due to its good local response and tolerable adverse-event profile. Photo courtesy of Dina Potter. Sunny Tree. 48" × 60". DocID: 1rePY - View Document
	OVC Crestword copy black read DocID: 1qyO0 - View Document